Annual report pursuant to Section 13 and 15(d)

FDA Refund

v3.19.3.a.u2
FDA Refund
12 Months Ended
Sep. 30, 2019
Receivables [Abstract]  
FDA REFUND

9. FDA REFUND

 

On August 29, 2018, the Company received notification from the Food and Drug Administration ("FDA") that the Company was being refunded $818,343 of 2016 product and establishment fees because the fees paid by the Company exceeded the costs of the FDA's review of the associated applications. The Company recorded the $818,343 receivable as other income during the year ended September 30, 2018 and received the refund on October 1, 2018.